BCLI

Brainstorm Cell Therapeutics Inc
2.69
0.59 (28.1%)
Upgrade to Real-Time
Afterhours (Closed)
2.69
Volume 566,996
Bid Price 2.55
Ask Price 2.66
News -
Day High 2.70

Low
1.0854

52 Week Range

High
4.70

Day Low 2.09
Company Name Stock Ticker Symbol Market Type
Brainstorm Cell Therapeutics Inc BCLI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.59 28.1% 2.69 19:05:10
Open Price Low Price High Price Close Price Prev Close
2.12 2.09 2.70 2.70 2.10
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,128 566,996 $ 2.40 $ 1,357,975 - 1.0854 - 4.70
Last Trade Time Type Quantity Stock Price Currency
18:50:04 10 $ 2.66 USD

Period:

Draw Mode:

Brainstorm Cell Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 98.30M 36.54M 33.70M $ - $ - -0.68 -2.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 6.60%

more financials information »

Brainstorm Cell Therapeu... News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BCLI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.562.701.491.86280,1301.1372.44%
1 Month1.752.701.34731.66239,6830.9453.71%
3 Months1.592.701.34731.66227,3101.1069.18%
6 Months2.684.701.08542.75246,6810.010.37%
1 Year3.104.701.08542.80155,000-0.41-13.23%
3 Years4.0617.951.08546.23505,318-1.37-33.74%
5 Years3.1817.951.08546.00338,631-0.49-15.41%

Brainstorm Cell Therapeu... Description

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.